KOL Corner: Amy Ellis Discusses Value-Based Cancer Rehab With Amanda Hodges

Amy Ellis, director of quality and value-based care at Northwest Medical Specialties, and Amanda Hodges, director of implementation for ReVital Cancer Rehabilitation, who acts as a bridge between the oncology world and the rehabilitation world, discuss overcoming barriers in practices to help patients with cancer get the rehab care they need, how patients with cancer can benefit from rehab, and defining value.

Related Videos

Related Content

Advertisement

November 21st 2024

FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

Cameron Santoro

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

November 21st 2024

Frameworks for Advancing Health Equity: Wellness Way

Giuliana Grossi

The Wellness Way facility was designed to improve access to comprehensive outpatient care and address social determinants of health for a diverse patient population.

November 21st 2024

Study Reveals Leukemia Transplant Successes and Persistent Relapse Risks

Kimberly Rath, PharmD

Long-term survival rates for patients with leukemia after hematopoietic cell transplantation (HCT) are encouraging but personalized transplant strategies remain important to improve outcomes.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 19th 2024

Drivers of Aggression Identified in Double-Expressor DLBCL

Jared Kaltwasser

Investigators say they may have found a new therapeutic target for patients with double-expressor diffuse large B-cell lymphoma (DLBCL).

November 18th 2024

Cardiomyopathy Risk Plummets When Sacubitril/Valsartan Taken With Chemo

Mary Caffrey

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.

Related Content

Advertisement

November 21st 2024

FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

Cameron Santoro

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

November 21st 2024

Frameworks for Advancing Health Equity: Wellness Way

Giuliana Grossi

The Wellness Way facility was designed to improve access to comprehensive outpatient care and address social determinants of health for a diverse patient population.

November 21st 2024

Study Reveals Leukemia Transplant Successes and Persistent Relapse Risks

Kimberly Rath, PharmD

Long-term survival rates for patients with leukemia after hematopoietic cell transplantation (HCT) are encouraging but personalized transplant strategies remain important to improve outcomes.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 19th 2024

Drivers of Aggression Identified in Double-Expressor DLBCL

Jared Kaltwasser

Investigators say they may have found a new therapeutic target for patients with double-expressor diffuse large B-cell lymphoma (DLBCL).

November 18th 2024

Cardiomyopathy Risk Plummets When Sacubitril/Valsartan Taken With Chemo

Mary Caffrey

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.